The UK and US have concluded a key bilateral deal that will preserve zero import taxes on British medicine shipments going into the US market.
Agreement Details of the Pact
In exchange for the tariff guarantee, the UK has committed to raise spending on medicines through the public health system. This pledge ensures that import taxes on these key exports will be held at nothing for a timeframe of the next three years.
This agreement follows previous warnings to hike import taxes on patented pharmaceutical imports, with figures mentioned up to 100%.
"This arrangement between the United Kingdom bolsters the international landscape for new treatments and establishes long-overdue equity to U.S.–U.K. pharmaceutical trade," a statement said.
Trade Significance
Pharmaceuticals are one of the the United Kingdom's biggest export categories to the United States, which is easily the largest buyer for large UK drugmakers.
Export figures reveal that in the 12 months leading up to last September, the UK sold medicines valued at billions to the US. This value accounted for 17.4% of British export trade in that period.
"This agreement secures employment, increases capital expenditure and sets the stage for the UK to emerge as a international leader for medical research," the Business and Trade Secretary commented.
Key NHS Changes
The deal entails several specific changes from the United Kingdom:
- Higher Cost Ceiling: The UK will raise the price threshold at which it considers new treatments to be unaffordable by a quarter.
- Boosted Medicine Funding: There is a target to raise overall NHS spending on treatments from 0.3% of GDP to 0.6 percent over the coming ten years.
- Refund Ceiling: The sum pharmaceutical firms must refund to the NHS to control costs will be restricted at 15%. Last year, refunds topped twenty percent.
Broader Context
The pact follows a long-running dispute between the pharmaceutical industry and the UK government over drug pricing and regulatory access.
This friction were heightened by claims that American patients were charged significantly more for the same drugs than people in the UK and Europe.
In recent months, several significant pharmaceutical investments in the UK have been halted or abandoned, while major investments have been pledged toward projects in the United States.
One official acknowledged that the NHS needed to invest a greater share on treatments, noting that its expenditure on drugs had shrunk as a percentage of its overall budget over the past decade.
